Cholera Vaccine  Market By Vaccine Type (Oral Cholera Vaccines, {Dukoral, Shanchol, Euvichol}, Injectable Cholera Vaccines, Combination Vaccines), By Disease Type (Endemic Cholera, Epidemic Cholera, Traveler’s Cholera), By Technology  (Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines), By End-User (Government and Public Health Organizations, Non-Governmental Organizations, Hospitals, and Clinics, Pharmaceutical and Vaccine Manufacturers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation vaccines

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Cholera Vaccine Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increasing incidence of cholera in endemic regions drives demand for vaccines.

3.2.2. Support from WHO and GAVI for cholera vaccination campaigns boosts market growth.

3.2.3. Introduction of new, affordable, and more effective oral vaccines enhances adoption.

3.3. Key industry pitfalls & challenges

3.3.1. Poor healthcare infrastructure in low-income regions restricts vaccine distribution.

3.3.2. Production and logistical costs challenge affordability in resource-limited settings.

3.3.3. Short-Term Immunity: Current vaccines require periodic doses, limiting long-term protection.

3.4. Market Opportunities

3.4.1. Expansion to Emerging Markets, Untapped regions in Africa and Asia present growth potential.

3.4.2. Government Collaborations and Partnerships for subsidized vaccine programs can increase coverage.

3.4.3. R&D Investment and Innovations in single-dose, long-lasting vaccines provide a competitive edge.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Cholera Vaccine Market, Vaccine Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Vaccine Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Oral Cholera Vaccines

4.2.1. Market Size and Forecast, 2025-2035 (USD Million)

4.2.2. Dukoral

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Million)

4.2.3. Shanchol

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Million)

4.2.4. Euvichol

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Million)

4.3. Injectable Cholera Vaccines

4.3.1. Market Size and Forecast, 2025-2035 (USD Million)

4.4. Combination Vaccines

4.4.1. Market Size and Forecast, 2025-2035 (USD Million)

5. Cholera Vaccine Market, By Disease Type Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Disease Type, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Endemic Cholera

5.2.1. Market Size and Forecast, 2025-2035 (USD Million)

5.3. Epidemic Cholera

5.3.1. Market Size and Forecast, 2025-2035 (USD Million)

5.4. Traveler’s Cholera

5.4.1. Market Size and Forecast, 2025-2035 (USD Million)

6. Cholera Vaccine Market, By Technology Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Technology 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Inactivated Vaccines

6.2.1. Market Size and Forecast, 2025-2035 (USD Million)

6.3. Live Attenuated Vaccines

6.3.1. Market Size and Forecast, 2025-2035 (USD Million)

6.4. Recombinant Vaccines

6.4.1. Market Size and Forecast, 2025-2035 (USD Million)

7. Cholera Vaccine Market, By End-User Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By End-User, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Government and Public Health Organizations

7.2.1. Market Size and Forecast, 2025-2035 (USD Million)

7.3. Non-Governmental Organizations

7.3.1. Market Size and Forecast, 2025-2035 (USD Million)

7.4. Hospitals and Clinics

7.4.1. Market Size and Forecast, 2025-2035 (USD Million)

7.5. Pharmaceutical and Vaccine Manufacturers

7.5.1. Market Size and Forecast, 2025-2035 (USD Million)

8. Cholera Vaccine Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Million)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Million)

8.2.2. North America Market Revenue, By Vaccine Type, 2025-2035

8.2.3. North America Market Revenue, By Disease Type, 2025-2035

8.2.4. North America Market Revenue, By Technology

8.2.5. North America Market Revenue, By End-User, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Vaccine Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Disease Type, 2025-2035

8.2.6.3. U.S. Market Revenue, By Technology

8.2.6.4. U.S. Market Revenue, By End-User, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Vaccine Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Disease Type, 2025-2035

8.2.7.3. Canada Market Revenue, By Technology

8.2.7.4. Canada Market Revenue, By End-User, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Million)

8.3.2. Europe Market Revenue, By Vaccine Type, 2025-2035

8.3.3. Europe Market Revenue, By Disease Type, 2025-2035

8.3.4. Europe Market Revenue, By Technology

8.3.5. Europe Market Revenue, By End-User, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Vaccine Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Disease Type, 2025-2035

8.3.6.3. Germany Market Revenue, By Technology

8.3.6.4. Germany Market Revenue, By End-User, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Vaccine Type, 2025-2035

8.3.7.2. France Market Revenue, By Disease Type, 2025-2035

8.3.7.3. France Market Revenue, By Technology

8.3.7.4. France Market Revenue, By End-User, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Vaccine Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Disease Type, 2025-2035

8.3.8.3. U.K. Market Revenue, By Technology

8.3.8.4. U.K. Market Revenue, By End-User, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Vaccine Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Disease Type, 2025-2035

8.3.9.3. Italy Market Revenue, By Technology

8.3.9.4. Italy Market Revenue, By End-User, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Vaccine Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Disease Type, 2025-2035

8.3.10.3. Spain Market Revenue, By Technology

8.3.10.4. Spain Market Revenue, By End-User, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Vaccine Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Disease Type, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Technology

8.3.11.4. Rest of Europe Market Revenue, By End-User, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Million)

8.4.2. Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Disease Type, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Technology

8.4.5. Asia Pacific Market Revenue, By End-User, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Vaccine Type, 2025-2035

8.4.6.2. China Market Revenue, By Disease Type, 2025-2035

8.4.6.3. China Market Revenue, By Technology

8.4.6.4. China Market Revenue, By End-User, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Vaccine Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Disease Type, 2025-2035

8.4.7.3. Japan Market Revenue, By Technology

8.4.7.4. Japan Market Revenue, By End-User, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Vaccine Type, 2025-2035

8.4.8.2. India Market Revenue, By Disease Type, 2025-2035

8.4.8.3. India Market Revenue, By Technology

8.4.8.4. India Market Revenue, By End-User, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Vaccine Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Disease Type, 2025-2035

8.4.9.3. Australia Market Revenue, By Technology

8.4.9.4. Australia Market Revenue, By End-User, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Vaccine Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Disease Type, 2025-2035

8.4.10.3. South Korea Market Revenue, By Technology

8.4.10.4. South Korea Market Revenue, By End-User, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Vaccine Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Disease Type, 2025-2035

8.4.11.3. Singapore Market Revenue, By Technology

8.4.11.4. Singapore Market Revenue, By End-User, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Disease Type, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Technology

8.4.12.4. Rest of Asia Pacific Market Revenue, By End-User, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Million)

8.5.2. Latin America Market Revenue, By Vaccine Type, 2025-2035

8.5.3. Latin America Market Revenue, By Disease Type, 2025-2035

8.5.4. Latin America Market Revenue, By Technology

8.5.5. Latin America Market Revenue, By End-User, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Vaccine Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Disease Type, 2025-2035

8.5.6.3. Brazil Market Revenue, By Technology

8.5.6.4. Brazil Market Revenue, By End-User, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Vaccine Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Disease Type, 2025-2035

8.5.7.3. Argentina Market Revenue, By Technology

8.5.7.4. Argentina Market Revenue, By End-User, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Vaccine Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Disease Type, 2025-2035

8.5.8.3. Mexico Market Revenue, By Technology

8.5.8.4. Mexico Market Revenue, By End-User, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Vaccine Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Disease Type, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Technology

8.5.9.4. Rest of Latin America Market Revenue, By End-User, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Million)

8.6.2. MEA Market Revenue, By Vaccine Type, 2025-2035

8.6.3. MEA Market Revenue, By Disease Type, 2025-2035

8.6.4. MEA Market Revenue, By Technology

8.6.5. MEA Market Revenue, By End-User, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Vaccine Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Disease Type, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Technology

8.6.6.4. GCC Countries Market Revenue, By End-User, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Vaccine Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Disease Type, 2025-2035

8.6.7.3. South Africa Market Revenue, By Technology

8.6.7.4. South Africa Market Revenue, By End-User, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Vaccine Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Disease Type, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Technology

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By End-User, 2025-2035

9. Company Profile

9.1. Valneva SE

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Sanofi Pasteur

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. PaxVax, Inc

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Serum Institute of India

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Euvichol

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Hilleman Laboratories

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. GlaxoSmithKline (GSK)

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. Johnson & Johnson

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Vabio tech

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. China National Biotec Group (CNBG)

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Biovac Institute

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Merck & Co.

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. Mylan Pharmaceuticals

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. Intas Pharmaceuticals

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. The Vaccine Initiative

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis